Advanced Enzyme Technologies Limited
ADVENZYMES · NSE · Basic Materials
With a 20% margin of safety, our buy-below price is ₹193.29.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%11.0%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✓Revenue growth > 10%22%
- ✓Earnings growing62%
- ✓Net margin ≥ 10%22.6%
- ✓Current ratio > 1.59.78
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 17.8
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (22.6%).
- •Financially solid — Altman Z 17.8.
Opportunities
- •Earnings growing (62% YoY).
- •Revenue growing (22% YoY).
Threats
- •Trades ~34% above our estimated fair value.
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing,
More in Basic Materials
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.